Relative clinical impact of epitype on CLL patient outcomes after separating patients by the related markers IGHV mutation status and ZAP70 positivity. (A) Patients were combined from the Mayo, CRC, and MDACC cohorts, and TTFT was plotted by epitype after segregating into 2 groups according to ZAP70 expression (±20% positivity, left panels) and IGHV status (±98% identity, right panels). (B) The same analysis as in (A), assessing OS from diagnosis. The P values were assessed using the log-rank test.